ClinicalTrials.gg
CompletedNCT02814565Updated Apr 8, 2019Results posted

Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

A Phase 3 interventional study of Cyclobenzaprine HCl and Placebo in Neck Pain, Back Pain and Spasm, sponsored by Takeda. Completed at 10 sites in Russian Federation. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-04-08.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study was to assess the effect of cyclobenzaprine hydrochloride (HCl) extended release (CER) 15 mg capsule once daily in participants with muscle spasms associated with acute painful musculoskeletal conditions.

Read the detailed description

The drug being tested in this study was cyclobenzaprine hydrochloride (HCl) extended-release (CER). CER was being tested to treat participants who had muscle spasms associated with acute painful musculoskeletal conditions. This study looked at medication helpfulness, relief from muscle spasms and pain, and improvement in range of motion and daily living activities.

The study enrolled 180 participants. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups which remained undisclosed to the participant and study doctor during the study:

  • CER 15 mg
  • Placebo (dummy inactive pill) - this was a capsule that looks like the study drug but had no active ingredient

All participants were asked to take one capsule at the same time each day throughout the study.

This multi-center trial was conducted in the Russian Federation. The overall time to participate in this study was up to 45 days. Participants made multiple visits to the clinic, and were contacted by telephone after the last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Neck Pain
  • Back Pain
  • Spasm

Keywords

  • Drug therapy
03

In context

Neck Pain

1,363 studies on the registry are indexed under Neck Pain; 300 are open to participants now.

This study's enrollment of 180 is above the median of 50 across 1,117 interventional studies indexed under Neck Pain.

Browse Neck Pain studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. Signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Is experiencing for no more than 14 days cervical or lower back pain (as assessed by the participant) due to muscle spasms (confirmed by the physician) associated with acute, painful musculoskeletal conditions.
  4. Is male or female and aged 18 to 50 years, inclusive.
  5. Female participants require to be either 2 years or surgically sterile by bilateral tubal ligation, hysterectomy, or bilateral oophorectomy, or, if premenopausal, had to be using an approved method.
  6. Female participants of must have a negative urine human chorionic gonadotropin (hCG) test result for pregnancy at study entry.
  7. After signing the informed consent form, the participant agrees not to make changes to dietary, exercise, or smoking habits and not to enter a weight loss program during his/her participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Has muscular pain secondary to acute trauma or fractures (e.g., due to osteoporosis). Such conditions could have been ruled out based on medical history, x-ray, or physical examination.
  2. Has received any compound within 30 days prior to Screening.
  3. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  4. Has a history of drug abuse or recent (within the last 12 months) history of excessive alcohol consumption defined as >2 drinks/day (>90 ml of 80 proof alcohol or equivalent).
  5. Has mild, moderate, severe liver impairment.
  6. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  7. Takes any concomitant medication including over-the-counter and herbal products for muscle spasms. If a participant is taking such medications, the medications has to be discontinued before starting the study.
  8. Takes or took within last 14 days medications, such as:

    1. selective serotonin reuptake inhibitors (SSRIs);
    2. serotonin norepinephrine reuptake inhibitors (SNRIs);
    3. tricyclic antidepressants (TCAs);
    4. monoamine oxidase (MAO) inhibitors;
    5. tramadol;
    6. bupropion;
    7. meperidine;
    8. verapamil;
    9. non- anti-inflammatory drugs (NSAIDs);
    10. topical anti-inflammatory medications
  9. Has a history or clinical manifestations of significant medical condition, such as:

    1. hyperthyroidism;
    2. acute recovery phase of myocardial infarction;
    3. arrhythmias, heart block or conduction disturbances;
    4. congestive heart failure;
    5. angle-closure glaucoma;
    6. urinary retention;
    7. increased intraocular pressure.
  10. Has abnormal physical findings or a medical condition that might have placed the participant at risk or interfered with the participant's ability to participate in the study.
  11. Has any known condition or disorder that might have affected absorption of the study drug.
  12. Has a history of or allergies to cyclobenzaprine and/or tricyclic antidepressants or any of their components.
  13. Has a history of hypersensitivity to any NSAIDs including salicylate sensitivity.
  14. Has a history of thrombocytopenia.
  15. Has a history of gastro-intestinal bleeding, cerebrovascular bleeding or other bleeding disorders.
  16. Had active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding)
  17. Has a history of severe renal impairment
  18. Had a major surgery during the 6 months preceding study entry.
  19. Has a language barrier or any other problems precluding good communication or cooperation.
  20. Has any reason to believe that he/she would not be able to complete the evaluations needed in this study.
  21. Has a known history of positive screen for surface antigen, antibody, or (HIV) antibody.
  22. Drug abuse in anamnesis.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Cyclobenzaprine HCl 15 mg

    Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.

    Drug: Cyclobenzaprine HCl

  • Placebo comparator
    Placebo

    Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.

    Drug: Placebo

Interventions

  • Cyclobenzaprine HCl extended-release capsules

    Also known as: Myorix®, AMRIX®

  • DrugPlacebo

    Cyclobenzaprine HCl extended release placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment

    Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: "How would you rate this study medication in improving your condition?" "0 = poor", "1 = fair", "2 = good", "3 = very good", "4 = excellent".

    Time frame: Day 3

Secondary outcomes

  1. Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Days 7 and 14 of Treatment

    Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: "How would you rate this study medication in improving your condition?" "0 = poor", "1 = fair", "2 = good", "3 = very good", "4 = excellent".

    Time frame: Days 7 and 14

  2. Percentage of Participants With Physician's Clinical Global Assessment on Day 3 of Treatment

    The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".

    Time frame: Day 3

  3. Percentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment

    The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".

    Time frame: Days 7 and 15

  4. Percentage of Participants With Subject-Rated Global Impression on Days 3, 7, and 14 of Treatment

    Participants assessed their clinical global impression based on relief from local pain, restriction in activities of daily living, restriction of movement and intensity of local pain on a daily basis. The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".

    Time frame: Days 3, 7, and 14

  5. Percentage of Responders on Days 3, 7, and 14 of Treatment

    A responder was defined as a participant who had both a rating of either "very good" or "excellent" for the participant's rating of medication helpfulness.

    Time frame: Days 3, 7, and 14

  6. Percentage of Participants With Physician Rated Assessment of Presence of Muscle Spasm on Days 3, 7, and 15 of Treatment

    The investigator assessment based on physical examination, presence of muscle spasm (presence of muscle spasm assessment). The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".

    Time frame: Days 3, 7, and 15

  7. Percentage of Participants With Physician Rated Assessment of Presence of Local Pain on Days 3, 7, and 15 of Treatment

    The investigator assessed local pain based on physical examination, reaction to palpation (presence of local pain assessment). The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".

    Time frame: Days 3, 7, and 15

  8. Percentage of Participants With Physician Rated Assessment of Limitation of Range of Motion on Days 3, 7, and 15 of Treatment

    The investigator assessed limitation of range of motion. The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".

    Time frame: Days 3, 7, and 15

  9. Percentage of Participants With Physician Rated Assessment of Limitation of Activities of Daily Living on Days 3, 7, and 15 of Treatment

    The investigator assessed limitation of activities based on evaluation of the patient's reported functional assessment. The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".

    Time frame: Days 3, 7, and 15

07

Results

Posted Apr 8, 2019

Participant flow

Participants took part in the study at 10 investigative sites in the Russian Federation from 12 October 2016 to 14 March 2017.

Participant flow — Overall Study
MilestoneCyclobenzaprine HCl 15 mgPlacebo
Started9090
Completed8988
Not completed12
Withdrew: Lack of efficacy01
Withdrew: Subject decision, caused by ae influenza11

Outcome measures

PrimaryPercentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment

Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: "How would you rate this study medication in improving your condition?" "0 = poor", "1 = fair", "2 = good", "3 = very good", "4 = excellent".

Time frame:
Day 3
Reported as:
Number · percentage of participants
Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment
percentage of participantsCyclobenzaprine HCl 15 mgPlacebo
Day 3, 0=poor20.028.9
Day 3, 1=fair60.046.7
Day 3, 2=good16.722.2
Day 3, 3=very good3.32.2
Day 3, 4=excellent0.00.0
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Rank Sum test · p = 0.6179
SecondaryPercentage of Participants With Subject's Rating of Medication Helpfulness Impression on Days 7 and 14 of Treatment

Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: "How would you rate this study medication in improving your condition?" "0 = poor", "1 = fair", "2 = good", "3 = very good", "4 = excellent".

Time frame:
Days 7 and 14
Reported as:
Number · percentage of participants
Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Days 7 and 14 of Treatment
percentage of participantsCyclobenzaprine HCl 15 mgPlacebo
Day 7, 0=poor7.816.7
Day 7, 1=fair41.134.4
Day 7, 2=good35.634.4
Day 7, 3=very good13.311.1
Day 7, 4=excellent2.23.3
Day 14, 0=poor8.914.4
Day 14, 1=fair25.625.6
Day 14, 2=good25.628.9
Day 14, 3=very good22.220.0
Day 14, 4=excellent17.811.1
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Rank Sum Test · p = 0.4338
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Rank Sum Test · p = 0.1657
SecondaryPercentage of Participants With Physician's Clinical Global Assessment on Day 3 of Treatment

The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".

Time frame:
Day 3
Reported as:
Number · percentage of participants
Percentage of Participants With Physician's Clinical Global Assessment on Day 3 of Treatment
percentage of participantsCyclobenzaprine HCl 15 mgPlacebo
Day 3, 1=worse1.10.0
Day 3, 2=no change52.268.9
Day 3, 3=slight improvement35.625.6
Day 3, 4=moderate improvement11.13.3
Day 3, 5=marked improvement0.02.2
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.0393
SecondaryPercentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment

The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".

Time frame:
Days 7 and 15
Reported as:
Number · percentage of participants
Percentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment
percentage of participantsCyclobenzaprine HCl 15 mgPlacebo
Day 7, 1=worse2.20.0
Day 7, 2=no change8.926.7
Day 7, 3=slight improvement52.244.4
Day 7, 4=moderate improvement27.824.4
Day 7, 5=marked improvement8.94.4
Day 15, 1=worse1.11.1
Day 15, 2=no change5.611.1
Day 15, 3=slight improvement27.834.4
Day 15, 4=moderate improvement30.032.2
Day 15, 5=marked improvement35.621.1
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.0330
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.0262
SecondaryPercentage of Participants With Subject-Rated Global Impression on Days 3, 7, and 14 of Treatment

Participants assessed their clinical global impression based on relief from local pain, restriction in activities of daily living, restriction of movement and intensity of local pain on a daily basis. The following 5-point rating scale was used: "1 = worse", "2 = no change", "3 = slight improvement", "4 = moderate improvement", "5 = marked improvement".

Time frame:
Days 3, 7, and 14
Reported as:
Number · percentage of participants
Percentage of Participants With Subject-Rated Global Impression on Days 3, 7, and 14 of Treatment
percentage of participantsCyclobenzaprine HCl 15 mgPlacebo
Day 3, 1=worse3.31.1
Day 3, 2=no change45.656.7
Day 3, 3=slight improvement47.833.3
Day 3, 4=moderate improvement3.37.8
Day 3, 5=marked improvement0.01.1
Day 7, 1=worse4.41.1
Day 7, 2=no change13.325.6
Day 7, 3=slight improvement52.243.3
Day 7, 4=moderate improvement22.225.6
Day 7, 5=marked improvement7.84.4
Day 14, 1=worse1.11.1
Day 14, 2=no change14.426.7
Day 14, 3=slight improvement24.420.0
Day 14, 4=moderate improvement27.828.9
Day 14, 5=marked improvement32.223.3
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.5756
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.4395
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.0905
SecondaryPercentage of Responders on Days 3, 7, and 14 of Treatment

A responder was defined as a participant who had both a rating of either "very good" or "excellent" for the participant's rating of medication helpfulness.

Time frame:
Days 3, 7, and 14
Reported as:
Number · percentage of participants
Percentage of Responders on Days 3, 7, and 14 of Treatment
percentage of participantsCyclobenzaprine HCl 15 mgPlacebo
Day 33.32.2
Day 715.614.4
Day 1440.031.1
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Fisher Exact · p = 1.0000
  • Cyclobenzaprine HCl 15 mg vs Placebo · Fisher Exact · p = 1.0000
  • Cyclobenzaprine HCl 15 mg vs Placebo · Fisher Exact · p = 0.2757
SecondaryPercentage of Participants With Physician Rated Assessment of Presence of Muscle Spasm on Days 3, 7, and 15 of Treatment

The investigator assessment based on physical examination, presence of muscle spasm (presence of muscle spasm assessment). The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".

Time frame:
Days 3, 7, and 15
Reported as:
Number · percentage of participants
Percentage of Participants With Physician Rated Assessment of Presence of Muscle Spasm on Days 3, 7, and 15 of Treatment
percentage of participantsCyclobenzaprine HCl 15 mgPlacebo
Day 3, 1=none2.22.2
Day 3, 2=mild27.821.1
Day 3, 3=moderate62.266.7
Day 3, 4=moderately severe7.810.0
Day 3, 5=severe0.00.0
Day 7, 1=none14.45.6
Day 7, 2=mild47.853.3
Day 7, 3=moderate37.838.9
Day 7, 4=moderately severe0.02.2
Day 7, 5=severe0.00.0
Day 15, 1=none48.932.2
Day 15, 2=mild37.847.8
Day 15, 3=moderate13.320.0
Day 15, 4=moderately severe0.00.0
Day 15, 5=severe0.00.0
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.3020
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.2367
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.0250
SecondaryPercentage of Participants With Physician Rated Assessment of Presence of Local Pain on Days 3, 7, and 15 of Treatment

The investigator assessed local pain based on physical examination, reaction to palpation (presence of local pain assessment). The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".

Time frame:
Days 3, 7, and 15
Reported as:
Number · percentage of participants
Percentage of Participants With Physician Rated Assessment of Presence of Local Pain on Days 3, 7, and 15 of Treatment
percentage of participantsCyclobenzaprine HCl 15 mgPlacebo
Day 3, 1=none1.11.1
Day 3, 2=mild24.421.1
Day 3, 3=moderate66.766.7
Day 3, 4=moderately severe7.811.1
Day 3, 5=severe0.00.0
Day 7, 1=none6.72.2
Day 7, 2=mild55.650.0
Day 7, 3=moderate36.746.7
Day 7, 4=moderately severe1.11.1
Day 7, 5=severe0.00.0
Day 15, 1=none35.625.6
Day 15, 2=mild51.150.0
Day 15, 3=moderate12.224.4
Day 15, 4=moderately severe1.10.0
Day 15, 5=severe0.00.0
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.4428
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.1163
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.0489
SecondaryPercentage of Participants With Physician Rated Assessment of Limitation of Range of Motion on Days 3, 7, and 15 of Treatment

The investigator assessed limitation of range of motion. The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".

Time frame:
Days 3, 7, and 15
Reported as:
Number · percentage of participants
Percentage of Participants With Physician Rated Assessment of Limitation of Range of Motion on Days 3, 7, and 15 of Treatment
percentage of participantsCyclobenzaprine HCl 15 mgPlacebo
Day 3, 1=none6.74.4
Day 3, 2=mild40.037.8
Day 3, 3=moderate47.852.2
Day 3, 4=moderately severe5.65.6
Day 3, 5=severe0.00.0
Day 7, 1=none22.213.3
Day 7, 2=mild51.151.1
Day 7, 3=moderate26.735.6
Day 7, 4=moderately severe0.00.0
Day 7, 5=severe0.00.0
Day 15, 1=none44.438.9
Day 15, 2=mild48.947.8
Day 15, 3=moderate6.713.3
Day 15, 4=moderately severe0.00.0
Day 15, 5=severe0.00.0
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.5275
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.0880
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.2542
SecondaryPercentage of Participants With Physician Rated Assessment of Limitation of Activities of Daily Living on Days 3, 7, and 15 of Treatment

The investigator assessed limitation of activities based on evaluation of the patient's reported functional assessment. The following 5-point rating scale was used: "1 = none", "2 = mild", "3 = moderate", "4 = moderately severe", "5 = severe".

Time frame:
Days 3, 7, and 15
Reported as:
Number · percentage of percentage
Percentage of Participants With Physician Rated Assessment of Limitation of Activities of Daily Living on Days 3, 7, and 15 of Treatment
percentage of percentageCyclobenzaprine HCl 15 mgPlacebo
Day 3, 1=none4.45.6
Day 3, 2=mild46.750.0
Day 3, 3=moderate46.738.9
Day 3, 4=moderately severe2.25.6
Day 3, 5=severe0.00.0
Day 7, 1=none18.910.0
Day 7, 2=mild62.263.3
Day 7, 3=moderate17.826.7
Day 7, 4=moderately severe1.10.0
Day 7, 5=severe0.00.0
Day 15, 1=none50.041.1
Day 15, 2=mild45.653.3
Day 15, 3=moderate4.45.6
Day 15, 4=moderately severe0.00.0
Day 15, 5=severe0.00.0
Statistical analysis
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.6920
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.0749
  • Cyclobenzaprine HCl 15 mg vs Placebo · Wilcoxon Sum Rank Test · p = 0.2371

Adverse events

Collected over First dose of study drug to within 30 days of last dose of study drug (Up to 45 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclobenzaprine HCl 15 mg0/90 (0%)0/90 (0%)21/90 (23.3%)
Placebo0/90 (0%)0/90 (0%)12/90 (13.3%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCyclobenzaprine HCl 15 mgPlacebo
SomnolenceNervous system disorders18/905/90
Dry mouthGastrointestinal disorders6/901/90
FlatulenceGastrointestinal disorders1/902/90
Poor quality sleepNervous system disorders1/902/90
TachycardiaCardiac disorders1/900/90
ToothacheGastrointestinal disorders1/900/90
InfluenzaInfections and infestations1/901/90
RhinitisInfections and infestations1/900/90
DizzinessNervous system disorders1/900/90
DysgeusiaNervous system disorders1/900/90

Baseline characteristics

Full Analysis Set (FAS) included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.

Age, Continuous
Age, Continuous(years)Cyclobenzaprine HCl 15 mgPlaceboTotal
Mean33.0 ± 9.031.5 ± 9.232.3 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Cyclobenzaprine HCl 15 mgPlaceboTotal
Female4862110
Male422870
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cyclobenzaprine HCl 15 mgPlaceboTotal
European (Caucasian)9090180
Region of Enrollment
Region of Enrollment(Participants)Cyclobenzaprine HCl 15 mgPlaceboTotal
Russia9090180
Smoking Status
Smoking Status(Participants)Cyclobenzaprine HCl 15 mgPlaceboTotal
Never smoked7879157
Former smoker134
Current smoker11819
Height
Height(cm)Cyclobenzaprine HCl 15 mgPlaceboTotal
Mean171.8 ± 8.2169.1 ± 7.6170.5 ± 8.0
Weight
Weight(kg)Cyclobenzaprine HCl 15 mgPlaceboTotal
Mean71.05 ± 14.5366.22 ± 13.6168.64 ± 14.25
08

Study locations

10 sites
  • Lipetsk, Lipetsk Region, Russian Federation
  • Saransk, Republic Of Mordovia, Russian Federation
  • Kazan, Republic Of Tatarstan, Russian Federation
  • Ekaterinburg, Sverdlovsk Region, Russian Federation
  • Moscow, Russian Federation
  • Nizhny Novgorod, Russian Federation
  • Novosibirsk, Russian Federation
  • Saint-Petersburg, Russian Federation
  • Tver, Russian Federation
  • Yaroslavl, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Feb 2017, 3 months.

Results were first posted in Apr 2019, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2016
First posted
Jun 27, 2016
StartActual
Oct 12, 2016
Primary completionActual
Feb 10, 2017
CompletionActual
Mar 14, 2017
Results first posted
Apr 8, 2019
Last update
Apr 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02814565
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 27, 2016
Start date
Oct 12, 2016
Primary completion
Feb 10, 2017
Completion
Mar 14, 2017
Results posted
Apr 8, 2019
Last update
Apr 8, 2019

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion